UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): December 16, 2016

 

Commission File No. 000-16929

 

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

 

DELAWARE   41-1505029
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification Number)
     

29 Emmons Drive,

Suite C-10

Princeton, NJ

  

 

 

08540

(Address of principal executive offices)   (Zip Code)

 

(609) 538-8200
(Issuer’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On December 16, 2016, Soligenix, Inc. (the “Company”) hosted an Investor Webcast on the origins of Innate Defense Regulators as a new drug class, as well as a review of oral mucositis and the recently announced and published Phase 2 clinical data for SGX942 (dusquetide) in the treatment of oral mucositis in head and neck cancer patients. The slides from this presentation are attached hereto as Exhibit 99.1.  The attached materials will also be posted on the Company’s website at www.soligenix.com.  The Company does not undertake to update this presentation.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)    Exhibits

 

Exhibit No.   Description
     
99.1   Presentation.

 

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Soligenix, Inc.

   
December 16, 2016  By:  /s/ Christopher J. Schaber 
    Christopher J. Schaber, Ph.D.
    President and Chief Executive Officer
    (Principal Executive Officer)

 

 3 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Presentation.

 

 

 

4